Xarelto Lawsuit Plaintiffs Draw Attention To BMJ Study Results Indicating Possible Twofold Increased Risk Of GI Bleeds

April 22, 2016 – – BloodThinnerHelp.com reports on the results of multiple studies from 2015 which seem to link new-generation blood thinner Xarelto to an increased risk for the development of severe bleeding episodes, such gastrointestinal and eye bleeds. As Xarelto controversies and investigations continue, and lawsuits filed in reference to the drug continue to grow in number, the public eye is closely watching multidistrict litigation number 2592. This MDL was formed by the U.S. Judicial Panel on Multidistrict Litigation (JPML) and currently involves over 2,800 Xarelto lawsuits. Plaintiffs who have filed Xarelto complaints have received support in their arguments from several 2015 studies which draw attention to some new concerns.

Xarelto is an anticoagulant drug which was approved by the FDA in 2011 to treat patients recovering from knee or hip replacement surgeries as well as those suffering from deep vein thrombosis, pulmonary embolism, and atrial fibrillation. The drug was very popular when it entered the market, as it offered users new freedoms that traditional blood thinners had been unable to. It was reported that it has since generated billions of dollars worth of sales for manufacturers Janssen Pharmaceuticals (a subdivision of corporate giant Johnson & Johnson) and Bayer AG.

A study which was published in JAMA Ophthalmology on June 25, 2015, noted that researchers had discovered a potential connection between use of rivaroxaban (generic Xarelto) and a heightened risk for the development of spontaneous vitreous hemorrhage, which is the medical term for an eye bleeding episode that occurs between the lens and retina areas. Following the study, researchers stated, “The risk of hemorrhage may be particularly elevated during the transition period when patients are switched from baseline anticoagulant to rivaroxaban therapy and are taking both anticoagulants simultaneously.”

Another study which was published in BMJ’s April 2015 issue also drew concern from patients. This study indicated that patients who took Xarelto (rivaroxaban) could be nearly two times as likely to suffer from gastrointestinal bleeding events when compared with those who took warfarin (a traditional blood thinner) instead. These researchers reported, “…we cannot rule out…a more than twofold higher risk of bleeding with rivaroxaban compared with warfarin.”

Attorney Joseph Osborne understands how concerning these test results could be for current Xarelto patients. He believes that as the current lawsuit plaintiffs await bellwether trials scheduled for early 2017, other cases are likely to continue to be filed into the MDL. He is working to help other patients who feel that they have been negatively affected after taking Xarelto, as these patients may be entitled to significant compensation attained through legal action. Patients who believe they were affected are encouraged to take advantage of the opportunity to fully evaluate their legal rights in the matter. To better assist these individuals, Attorney Osborne is currently offering free legal consultations to qualified parties.

To request additional information, or to ask questions, please contact Attorney Joseph Osborne by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60009559